HRT Access in Australia: The Definitive Guide

How do you get menopause treatment in Australia?

Arrange an assessment with a GP or another appropriate clinician, then check the prescribed medicine with your pharmacy. Bring the symptoms you want help with, menstrual history, current medicines and relevant health history. Ask who will provide follow-up and how much the consultation costs after any Medicare rebate.

Medicare assessment, PBS subsidy and pharmacy availability are different parts of access. A medicine can be prescribed yet not meet a particular PBS condition; an eligible prescription can still face a supply problem. This page helps you check those parts without selecting a regimen for you. [1], [2], [4]

What should the access pathway cover?

Keep a copy of the agreed instructions. A pharmacy subsidy listing identifies a product and benefit conditions; it is not an instruction to start treatment. [1], [2], [4]

What is the Medicare menopause assessment?

Services Australia lists items 695 and 19000 for assessment of menopause or perimenopause symptoms. They require at least 20 minutes and can be billed once every 12 months when the criteria are met. The initial availability period began July 1, 2025 and lasts two years. [1]

Ask the practice whether the appointment and clinician meet the item requirements and whether it will be bulk billed or leave a gap. The assessment item does not guarantee a particular prescription, an immediate specialist appointment or payment for every test. Describe your priorities so the time addresses the issues that matter to you.

What might a PBS prescription cost?

In 2026 the general PBS copayment is A$25, with the concessional copayment A$7.70. These are PBS rules, not the price of every HRT product or private prescription. Eligibility, the item, any brand premium and the actual supply still matter. The live Estrogel Pro page showed an A$25 general patient charge when checked. [2], [3]

The 2025 women’s health measures added Estrogel, Prometrium and Estrogel Pro to the PBS. Do not use the announcement’s historical savings estimate as a quote for your current regimen. Ask the pharmacy to price the complete prescription, including any separate progestogen or local vaginal treatment. [5]

What is happening with patch supply?

TGA’s September 14, 2026 update estimated return to normal supply on December 31, 2026 for Estradot 25, 50, 75 and 100, and October 30, 2026 for Estraderm MX 50 and 100. Several other strengths and combination products were marked resolved. These dates can change and do not establish what an individual pharmacy has today. [4]

Ask the pharmacist about the prescribed product, available alternatives and the permitted substitution pathway. TGA describes substitutions under specified circumstances, sometimes using another brand or lower-strength patches to deliver the prescribed rate. The pharmacist must explain differences and may need the prescriber’s involvement. Do not cut patches or construct a substitute yourself. [4]

Will an alternative patch have the same subsidy?

Not necessarily. TGA specifically separates authorized supply from PBS treatment under the scarcity substitution instrument. Its current guidance says Estramon packs require a new prescription to receive PBS subsidy rather than dispensing under that instrument, because pack sizes differ. Estraderm MX 75 is another named non-PBS example. [4]

Before accepting a substitute, confirm the amount payable, number of patches, replacement interval and remaining repeats. The whole regimen must still make sense, including uterine protection where needed. If no suitable alternative can be supplied, ask the prescriber for an agreed plan rather than waiting until you have no medicine left.

What should you record after a change?

Keep the actual brand, strength, application instructions and date of any pharmacist or prescriber-directed change. Note problems with adhesion or skin irritation and how symptoms or unwanted effects change. A record provides context; it cannot diagnose absorption or prove that a different brand caused every symptom.

Agree when to review treatment and how to report problems earlier. Do not let a supply discussion replace assessment of concerning symptoms. The monitoring guide explains the difference between a useful record and a universal hormone target.

What do public questions highlight?

A selected public Australian discussion asked about consultation expense and finding care when symptoms begin before the usual menopause age. It illustrates uncertainty about the route through care, not how often a clinician refuses treatment or which prescription is right. No individual history or proposed regimen is reproduced here. [6]

Ask a clinic about its scope, fees and follow-up before booking. If your situation is complex, ask who can assess it and whether a referral is needed. Advice from another patient cannot confirm Medicare eligibility or replace a clinical assessment.

Common Australian access questions

Is MHT different from HRT?

In this menopause context, the terms describe the same treatment category. The actual medicine and indication still matter.

MHT means menopausal hormone therapy, while HRT means hormone replacement therapy. Neither term identifies the exact formulation, eligibility for a subsidy or the instructions for using it. When discussing access, bring the product name, strength and route so the practice and pharmacy can check the same prescription. The access pathway separates clinical assessment, payment and pharmacy supply. [1], [2]

Does the assessment rebate make every consultation free?

No. Confirm eligibility and the practice’s billing arrangement. [1]

A Medicare benefit is a payment mechanism with specified requirements, not a promise that every practice charges the same fee. Ask what the appointment includes, whether the relevant item can be claimed and what remains payable. Also distinguish assessment costs from prescription costs and later follow-up. The assessment section explains the current item and timing requirements without promising a zero-cost visit. [1]

Does PBS listing guarantee the pharmacy has stock?

No. Subsidy and supply are separate; check both. [2], [4]

A PBS entry answers a subsidy question; stock depends on the product and the pharmacy’s ability to obtain it. Verify the exact strength and presentation rather than assuming another listed patch is available or equivalent. If there is a shortage, ask about the permitted replacement pathway and its cost before the next supply is needed. See patch supply and substitution. [2], [4]

Can I switch patches myself during a shortage?

No. The TGA pathway is for permitted pharmacist substitutions and prescriber advice, with product-specific instructions. [4]

Bring the existing prescription and packaging so the pharmacist can identify which current shortage arrangement, if any, applies. Confirm how to use the replacement and whether the prescriber needs to be involved. Do not improvise by cutting patches or changing the number used. The substitution section explains why permission to substitute and reimbursement must both be checked for the specific product. [4]

Are the estimated return dates reliable enough to delay a refill plan?

They can change. Contact the pharmacist while you still have supply and agree what to do if the product remains unavailable. [4]

The dates in this guide are dated estimates from the current shortage information, not guarantees about your local pharmacy. Ask when to recheck supply and who to contact if a replacement is needed. Record any agreed product change so later instructions refer to the medicine you actually received. The supply section links the official information and distinguishes the affected strengths. [4]

Glossary

Terms used at the clinic and pharmacy.

Active ingredient

The substance intended to produce the medicine’s effect.

Brand

The commercial name on a medicine’s packaging.

Compounded preparation

A medicine prepared to an individual formula, distinct from an approved finished product.

Continuity of care

Keeping prescribing, supply and follow-up connected over time.

Copayment

The portion of a covered prescription cost you pay.

Deductible

An amount you may need to pay before a plan contributes.

Dispensing

Pharmacy supply of a medicine with the appropriate instructions.

Formulary

A payer’s list of medicines and coverage conditions.

Formulation

The preparation supplied, such as a tablet, gel or patch.

Generic medicine

A regulated version of a named medicine with its own authorized product information.

HRT / MHT

Hormone replacement therapy or menopausal hormone therapy; this library covers menopause care.

Local vaginal treatment

Treatment intended mainly for vaginal and related urinary symptoms.

Marketing authorization

Regulatory permission for a particular medicine; separate from stock or coverage.

Prior authorization

A coverage approval that a payer may require before paying.

Progestogen

The hormone group commonly used to protect the uterine lining with systemic estrogen.

Refill or repeat

A further supply authorized by an existing prescription.

Reimbursement

Payment by a public program or insurer under its eligibility rules.

Route

How a medicine is administered, such as by mouth or through the skin.

Strength

The stated amount or concentration; its meaning depends on the formulation.

Systemic treatment

Medicine that reaches the circulation and acts beyond the application site.

How was this guide researched?

Sources and limits

This AI-assisted guide prioritizes the public bodies responsible for access, regulatory information and original clinical guidance. The source directory records dates, locations and access limits. No clinician review is claimed. Doserly develops a commercial tracking app. Figures are original explanatory summaries; captures show real features with fictional data.

Amounts and policies were checked October 2, 2026. A published policy confirms neither your eligibility, local stock nor treatment suitability. Public discussions identify questions; they do not measure care quality. Send corrections to Doserly support with the relevant source.

Sources